Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
Status PubMed-not-MEDLINE Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24327932
PubMed Central
PMC3850022
DOI
10.4161/onci.25619
PII: 2013ONCOIMM0166
Knihovny.cz E-resources
- Keywords
- FoxP3, T regulatory cells, disease progression, immune suppression, multiple myeloma, suppressor cells,
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Multiple myeloma (MM) patients exhibit consistent degrees of immune dysfunction. Regulatory T cells contribute to the establishment of an immunosuppressive status in MM patients, hence favoring disease progression.
See more in PubMed
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9. doi: 10.1038/leu.2008.291. PubMed DOI PMC
Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7:e47077. doi: 10.1371/journal.pone.0047077. PubMed DOI PMC
Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One. 2012;7:e35981. doi: 10.1371/journal.pone.0035981. PubMed DOI PMC
Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol. 2005;2:11–9. PubMed
Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One. 2012;7:e49446. doi: 10.1371/journal.pone.0049446. PubMed DOI PMC
Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma. 2012;53:1406–8. doi: 10.3109/10428194.2011.652106. PubMed DOI
Muthu Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hájek R. Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry Part B: Clinical Cytometry. 2013 doi: 10.1002/cytob.21109. Forthcoming. PubMed DOI
Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10:155–67. doi: 10.2174/156800910791054239. PubMed DOI
Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605–13. doi: 10.1182/blood-2010-04-278432. PubMed DOI
